Currently Viewing:
Supplements Examining Therapies for Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy: Considerations for Diagnosis, Management, and Population Health
Melody Ryan, PharmD, MPH, and Stephen J. Ryan, MD, MA
Currently Reading
The Economic Burden and Managed Care Implications of Chronic Inflammatory Demyelinating Polyneuropathy
Gary M. Owens, MD

The Economic Burden and Managed Care Implications of Chronic Inflammatory Demyelinating Polyneuropathy

Gary M. Owens, MD
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a symmetric demyelinating peripheral neuropathy with either a progressive or relapsing remitting course. CIDP is both debilitating and degenerative, leaving patients with functional impairment due to nerve damage in their extremities. Along with its medical burden, CIDP has a significant economic impact, with disease-related expenses and the often fairly high costs related to the immune therapies used to treat the disease. Costs for patients with this disorder often exceed those of other immune-mediated neuromuscular diseases. For these reasons, it is necessary for clinicians to better determine optimal long-term treatment strategies for patients with CIDP that are designed to address both the clinical and economic burden of its management and improve patient outcomes and quality of life.
Am J Manag Care. 2018;24:-S0
Although the clinical burden of chronic inflammatory demyelinating polyneuropathy (CIDP) has been well documented, its economic burden has been more difficult to estimate and address. Regarding direct costs of disease, limited information has been available on the hospitalization burden associated with CIDP. One study presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in May 2016 by Suryavanshi and Khanna used data surrounding discharges of adult patients 18 years and older with CIDP identified from the 2010 pooled Healthcare Cost and Utilization Project National (Nationwide) Inpatient Sample (HCUP-NIS). Patients with CIDP-related hospitalizations were matched with 4 control hospitalizations based on gender and age. The study used survey formats to determine predictors of length of stay (LOS), total charges, predictors of death, and CIDP treatment (intravenous immunoglobulin [IVIg] vs plasmapheresis). There were 31,451 weighted records of CIDP hospitalization during the study period. Results reported that the estimated cost of hospitalizations for CIDP from 2010 to 2012 was $2.1 billion in the United States alone. The mean cost of CIDP-related hospitalization was $68,231 and related to 50% longer LOS and higher total charges than control patients without CIDP. Significant predictors of hospitalization outcomes included patient age, hospital bed size, location and teaching status, discharge to long-term care or skilled nursing facilities, presence of complications, administration of IVIg or plasmapheresis treatments, and higher diagnosis and procedures on record. The authors concluded that although CIDP is a rare disease, it still results in significant hospitalization costs and burden. Although these data were presented as noted at the ISPOR Congress, they have not yet been formally published.1

Another important study was performed by Guptill et al to determine health plan–paid costs and healthcare resource usage of patients with CIDP who were enrolled in 9 commercial health plans in the United States and submitted claims during the 12-month period for the year 2011. The study assessed demographics, prevalence of comorbidities, prescribed drugs, place and service, and the mean annual healthcare costs paid for each patient. To be included, patients must have had at least 1 health insurance claim during the study period. Data were obtained from a variety of health plans, including commercial, Medicare, and Medicaid plans.2 Patients included those with a CIDP diagnosis between January 1, 2011, and December 31, 2011, whose primary health insurance plan was considered eligible for the Accordant Health Services (AHS) care management program, a nationwide medical and pharmacy claims database.2,3

Total costs were calculated per patient, and this amount was divided by total member-months and multiplied by 12 to determine per-patient per-year (PPPY) costs. Paid costs were categorized as either medical or pharmacy costs. Results demonstrated that mean health plan-paid costs for patients with CIDP during the study period were $56,953 (± $10,292). Medical costs were $25,054 (± $6840) and pharmacy costs were calculated at $31,899 (± $7375). Overall costs were lower for women ($47,094 ± $15,560) versus men ($64,648 ± $13,747). There was no evidence for a significant relationship between the health insurance–paid costs PPPY and either age or comorbidity burden. Pharmacy costs accounted for 57% of the total paid amounts from the health plans included. Health plan–paid costs that were incurred during hospitalization comprised 18% of total insurance paid amounts, with 16% of paid costs attributed to the outpatient hospital setting and 3% to physician offices. Approximately 90% of pharmacy costs were related to IVIg therapy, which was administered to 26% of patients included in the study. Overall costs and pharmacy costs were highly variable among the patient population studied. The distribution of total health care plan costs by place or service and/or claim category was divided as shown in the Figure.2

Overall, the investigators concluded that the mean annual health plan–paid costs for patients with CIDP were higher than those attributed to other recently studied immune-mediated neuromuscular diseases (eg, myasthenia gravis). Future studies are needed to better delineate optimal long-term treatment strategies for patients with CIDP, especially with attention to therapy use and cost.2

Cost Utility of Therapy for CIDP

CIDP was previously treated using corticosteroids and plasma exchange (PE); however, these therapies were limited by disease chronicity. Long-term use of steroids carried a substantial risk of serious adverse events (AEs), and the benefit from PE was usually transient, requiring access to specialized treatment centers and repeated vascular access.2 The first IVIg agent was approved for use by the FDA in 2008; IVIg was widely used off label before FDA approval of the drug class, but it is now considered first-line treatment for CIDP.2,4,5

Looking at the drug class in general, IVIg is used as therapy for more conditions than CIDP. Per a recent market analysis report, the World Health Organization identified more than 50 primary immunodeficiency diseases (PIDDs), including 176 rare hereditary disorders. The overall incidence of PIDDs is growing, which will likely increase demand for immunoglobulin therapies over the next several years. Results of market research data have estimated the global IVIg market size at $9.09 billion (2016 USD), and this market is predicted to grow at a compound annual growth rate of 7.1% in the 10-year period from 2012 to 2022. Demand for IVIg in both PIDDs and acquired immunodeficiency disorders continues to rise as IVIg is the most effective and often the single available treatment option for these disorders. Recent marketing data show that the CIDP segment held the largest share of the IVIg market based on application, second only to hypogammaglobulinemia.6

Administration of IVIg constituted the greatest revenue share as of 2014, based on high usage of IVIg in a substantial range of indications and applications. The increasing number of intravenous (IV) product approvals and clinical trials for new applications will likely continue industry growth opportunities in this area. That said, subcutaneous (SC) administration of immunoglobulin is predicted to grow exponentially at a rate of 9.8% over the 2012-2022 forecast period. Growth potential of this segment of therapy is associated with the advantages of SC administration, which include the rapid action of the drug once administered, faster patient responses, and fewer AEs associated with these formulations.6 It also must be noted that the overall drug category of “inflammatory medications” is a significant cost driver in healthcare. A 2017 Express Scripts Drug Trend Report demonstrated that inflammatory agents remain the costliest category in terms of spending and is one of the highest in expected continued spending by trend. The anti-inflammatory category is dominated by specialty drugs and remains the leading pharmaceutical cost driver for health plans. However, treatments for other diseases of aging, including cancer and diabetes, overtake anti-inflammatory drugs as patients age, as evidenced by anti-inflammatory drugs holding third place in this patient population.7

Although IVIg has demonstrated significant clinical improvement for patients with CIDP, it remains a considerably more expensive therapy than standard corticosteroids. Because of this, the predicted cost-utility of IVIg drugs must be taken into consideration along with their clinical efficacy. One analysis in this area was performed by Blackhouse et al and compared the cost-utility of these drugs versus corticosteroids in a Canadian patient population with CIDP. This study was performed using a Markov model and drawn from the perspective of a publicly funded healthcare system in Canada, noting that the costs of IVIg were paid by public health payers as part of their payment to Canadian Blood Services (CBS). Effectiveness was measured in quality-adjusted life-years (QALYs). The time model was 5 years in the basecase analysis, and alternative time models were assumed in the sensitivity analysis. Costs and effects were also discounted at a rate of 5% per year. Basecase results demonstrated that the total costs of IVIg over the 5-year period were $124,065 (3.962 QALYs) versus $2196 for corticosteroids (3.785 QALYs). This represented an incremental cost for IVIg of $121,869 compared with corticosteroids. The cost-utility ratio of IVIg compared with corticosteroids was calculated at $687,287 per QALY gained. The data suggested that, based on common willingness-to-pay thresholds, the use of IVIg drugs in CDIP would be considered cost-effective. However, the investigators acknowledged limitations to the study, including that a public health payer perspective was used and, because of this, indirect costs were not included in the analysis. If an actual societal perspective had been considered, the cost-utility of IVIg use may have shown more encouraging results. The investigators noted that IVIg remains a popular therapy due to its potential for more optimal patient outcomes versus less expensive, standard therapies.4

In the more recent Guptill study published in 2014, a total of 179 health insurance claims were paid among patients with CIDP who received IVIg. In this analysis, the majority of the IVIg infusions were done in the home setting (72%), with 16% administered in a physician’s office and 12% administered in either an outpatient hospital or other point-of-service (POS) setting (11% and 1%, respectively). The mean PPPY cost for patients treated with IVIg was $108,016 (± $118,437; range, $4998-$248,938), and the paid amount per IVIg infusion was $8598 (± $476; range, $950-$24,458). Per-infusion costs were almost the same in the home setting ($9720 ± $561) compared with the outpatient setting ($9718 ± $951). Total paid costs for IVIg infusions administered in the clinic setting were $2610 (± $118). As noted earlier, the chronic management of CIDP with IVIg leads to considerable long-term treatment costs. However, given the proven efficacy of IVIg in this disease, studies need to be performed to determine long-term management strategies using these agents, especially in terms of dosing, dose intervals, and tapering, to both maximize treatment efficacy and justify the high costs of therapy over the long term.2

Reducing Costs of IVIg Therapy

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up